Top Page
Austco Healthcare Limited
(Sydney:AHC)
Austco Healthcare Limited (AHC) vs. iShares MSCI Australia ETF (EWA)
Austco Healthcare Limited Business Overview & Revenue Model
Austco Healthcare Limited Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 72.22M | 81.41M | 58.15M | 41.98M | 35.88M | 31.25M |
| Gross Profit | 37.67M | 42.37M | 30.67M | 6.68M | 18.85M | 16.71M |
| EBITDA | 10.64M | 11.10M | 8.11M | 3.60M | 3.52M | 3.13M |
| Net Income | 8.84M | 5.93M | 7.08M | 2.26M | 2.33M | 3.42M |
Balance Sheet | ||||||
| Total Assets | 74.28M | 91.07M | 68.70M | 37.85M | 34.03M | 27.18M |
| Cash, Cash Equivalents and Short-Term Investments | 14.91M | 14.48M | 13.56M | 4.67M | 7.63M | 7.77M |
| Total Debt | 2.24M | 3.88M | 1.78M | 524.00K | 979.00K | 1.15M |
| Total Liabilities | 25.17M | 39.34M | 24.33M | 12.85M | 10.94M | 7.88M |
| Stockholders Equity | 49.11M | 51.73M | 44.38M | 25.00M | 23.09M | 19.30M |
Cash Flow | ||||||
| Free Cash Flow | 10.14M | 10.66M | 7.45M | -1.25M | 315.00K | 1.91M |
| Operating Cash Flow | 11.72M | 13.42M | 11.35M | 320.00K | 1.94M | 3.21M |
| Investing Cash Flow | -14.16M | -12.32M | -11.06M | -1.57M | -1.63M | -1.30M |
| Financing Cash Flow | 15.13M | -402.00K | 8.84M | -1.58M | -312.00K | -474.00K |
Austco Healthcare Limited Technical Analysis
Austco Healthcare Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | AU$151.77M | 24.85 | 12.35% | ― | 39.98% | -30.04% | |
54 Neutral | AU$131.18M | ― | -4.28% | ― | 7.38% | 82.39% | |
53 Neutral | AU$897.90M | ― | -44.49% | ― | 55.91% | 22.60% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
42 Neutral | AU$81.13M | ― | -31.98% | ― | 34.20% | -23.90% | |
40 Underperform | AU$89.08M | ― | ― | ― | ― | ― | |
40 Underperform | AU$110.28M | ― | -47.98% | ― | 700.00% | 26.88% |
Austco Healthcare Limited Corporate Events
Austco Healthcare Limited has announced the issuance of 106,207 fully paid ordinary securities under an employee incentive scheme. This move is part of the company’s strategy to motivate and retain its workforce, potentially impacting its operational efficiency and market competitiveness positively.
The most recent analyst rating on (AU:AHC) stock is a Buy with a A$0.45 price target. To see the full list of analyst forecasts on Austco Healthcare Limited stock, see the AU:AHC Stock Forecast page.
Austco Healthcare Limited has announced the issuance of 1,085,038 ordinary fully paid securities to be quoted on the ASX as part of an employee incentive scheme. This move is expected to strengthen the company’s operational capabilities and enhance its market positioning by aligning employee interests with corporate growth objectives.
The most recent analyst rating on (AU:AHC) stock is a Buy with a A$0.50 price target. To see the full list of analyst forecasts on Austco Healthcare Limited stock, see the AU:AHC Stock Forecast page.
Austco Healthcare Limited announced a significant financial performance for the year ending June 30, 2025, with a revenue increase of over 37% and EBITDA growth exceeding 54%. This growth was driven by both organic operations and strategic acquisitions, including the successful integration of Amentco Enterprise Group Pty Ltd and G&S Technologies Limited. The company funded these acquisitions through operating cash flows, maintaining a strong cash position. The strong performance of Amentco led to a higher-than-expected earn-out payment, impacting statutory net profit but not EBITDA. Austco’s CEO highlighted the transformative nature of FY25, emphasizing the company’s robust contracted revenue and strategic execution, positioning it confidently for FY26.
The most recent analyst rating on (AU:AHC) stock is a Buy with a A$0.45 price target. To see the full list of analyst forecasts on Austco Healthcare Limited stock, see the AU:AHC Stock Forecast page.
Austco Healthcare Limited has announced the quotation of 247,363 ordinary fully paid securities on the ASX, issued under an employee incentive scheme. This move is part of the company’s strategy to enhance its market presence and incentivize its workforce, potentially impacting its operational dynamics and stakeholder engagement positively.
The most recent analyst rating on (AU:AHC) stock is a Buy with a A$0.45 price target. To see the full list of analyst forecasts on Austco Healthcare Limited stock, see the AU:AHC Stock Forecast page.
Austco Healthcare Limited has announced a change in the interests of a substantial shareholder, as reported by Australian Ethical Investment Limited. The voting power of the substantial holder has decreased from 15.59% to 14.06%, indicating a reduction in their stake in the company. This change could have implications for Austco Healthcare’s shareholder dynamics and influence within the company.
The most recent analyst rating on (AU:AHC) stock is a Buy with a A$0.45 price target. To see the full list of analyst forecasts on Austco Healthcare Limited stock, see the AU:AHC Stock Forecast page.
Austco Healthcare Limited has completed the acquisition of New Zealand-based G&S Technologies, a company renowned for its expertise in Nurse Call systems, RTLS, CCTV, and other integrated security and communication systems, particularly in the healthcare and aged care sectors. This strategic acquisition is intended to bolster Austco’s direct sales capabilities, accelerate growth, and expand its range of solutions to better serve the healthcare markets. The acquisition was funded through existing cash reserves and includes provisions for earnout payments based on future performance, reflecting Austco’s commitment to enhancing its market position and delivering value to stakeholders.
The most recent analyst rating on (AU:AHC) stock is a Buy with a A$0.45 price target. To see the full list of analyst forecasts on Austco Healthcare Limited stock, see the AU:AHC Stock Forecast page.
Austco Healthcare Limited has secured a AUD $2.1 million contract to implement its advanced nurse call platform, Tacera, at the new patient and surgical tower of Toronto Western Hospital, part of the University Health Network. This project, part of a $1 billion investment by Ontario, is expected to enhance healthcare delivery with real-time clinical communication and integration with hospital systems, supporting Austco’s North American growth strategy and reinforcing its position as a leader in innovative healthcare solutions.
The most recent analyst rating on (AU:AHC) stock is a Buy with a A$0.45 price target. To see the full list of analyst forecasts on Austco Healthcare Limited stock, see the AU:AHC Stock Forecast page.
Austco Healthcare Limited has renewed its preferred supplier agreement with a major US healthcare provider, continuing to supply and support its Tacera IP Nurse Call systems across approximately 180 healthcare facilities in over 30 US states. This renewal builds on a previous five-year agreement that generated over A$49 million in revenue and reinforces Austco’s position as a leader in digital nurse call and patient management solutions. The company is also shifting production away from China to mitigate tariff challenges, a move expected to be completed in the next few months.